What are the side effects of Pertuzumab?

In clinical trials of pertuzumab (Pertuzumab) combined with other drugs for the treatment of metastatic breast cancer, such as trastuzumab, docetaxel, etc., more than half of the users experienced side effects including diarrhea, alopecia and neutropenia; more than 10% experienced neutropenia and leukopenia accompanied by fever. After marketing, cases of tumor lysis syndrome (TLS) may occur in patients.

The most common adverse reactions reported by some patients after discontinuing docetaxel are diarrhea, upper respiratory tract infection, rash, headache, fatigue, swelling of the nose and throat (often due to colds), weakness, itching, joint pain, nausea, pain in the extremities, and back pain. In clinical trials of the pertuzumab combination in the neoadjuvant setting for breast cancer, more than 50% of people experienced alopecia and neutropenia. Hyperuricemia, hyperphosphatemia, and acute renal failure may indicate the development of TLS, and patients with significant tumor burden (e.g., large metastases) may be at higher risk.

Pertuzumab is a strictly controlled drug. The original drug has been marketed in China and has entered the ranks of medical insurance, but it is only reimbursed for patients who meet the indications. The price of each box may be more than more than 5,000 yuan, and the price of the Hong Kong version may be more than 20,000 yuan (the price may fluctuate due to exchange rates). The price of each box of the European version of Pertuzumab's original drug marketed overseas may be more than 10,000 yuan, and the price of each box of the Turkish version may be more than 6,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the domestic and foreign original drugs are basically the same, and there are currently no generic versions of Pertuzumab on the market.